Top

Published in:

Open Access 01-12-2014 | Case Report

The Changing Role for Endomyocardial Biopsy in the Diagnosis of Giant-Cell Myocarditis

Authors: Ankur Kalra, Rachel Kneeland, Michael A. Samara, Leslie T. Cooper Jr.

Published in: Cardiology and Therapy | Issue 1-2/2014

Abstract

Endomyocardial biopsy (EMB) is central to the diagnosis of giant-cell myocarditis (GCM) and planning further management. There is, however, no guideline-directed recommendation on re-biopsy or left ventricular EMB in a suspected case of acute, fulminant myocarditis following an indeterminate first biopsy. This manuscript illustrates, with a case, the changing role for EMB in the current era in the diagnosis of GCM.

Available only for authorised users

Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526–38.PubMedCrossRef

Ukena C, Mahfoud F, Kindermann I, Kandolf R, Kindermann M, Böhm M. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail. 2011;13(4):398–405.PubMedCrossRef

Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18(6):733–46.PubMedCrossRef

Sakakibara S, Konno S. Endomyocardial biopsy. Jpn Heart J. 1962;3(69):537–43.PubMedCrossRef

Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.PubMedCrossRef

McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (Nonfulminant) myocarditis. N Engl J Med. 2000;342(10):690–5.PubMedCrossRef

Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593–5.PubMedCrossRef

Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.PubMedCrossRef

Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–48, 2648a–2648d.

10.

Shields RC, Tazelaar HD, Berry GJ, Cooper LT Jr. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail. 2002;8(2):74–8.PubMedCrossRef

11.

Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303–9.PubMedCrossRef

12.

Cooper LT Jr, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102:1535–9.PubMedCentralPubMedCrossRef

13.

Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250–8.PubMedCrossRef

14.

Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies. A retrospective study over a 28-year period. Circulation. 2013;128(14):1531–41.PubMedCrossRef

15.

Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245–74.PubMedCrossRef

16.

Basso C, Ronco F, Marcus F, et al. Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur Heart J. 2008;29:2760–71.PubMedCrossRef

17.

Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900–9.PubMedCrossRef

18.

Cooper LT Jr. The role of left ventricular biopsy in the management of heart disease. Circulation. 2013;128(14):1492–4.PubMedCrossRef

19.

Kandolin R, Lehtonen J, Salmenkibi K, et al. Diagnosis, treatment and outcome of giant cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15–22.PubMedCrossRef

Title: The Changing Role for Endomyocardial Biopsy in the Diagnosis of Giant-Cell Myocarditis
Authors: Ankur Kalra
Rachel Kneeland
Michael A. Samara
Leslie T. Cooper Jr.
Publication date: 01-12-2014
Publisher: Springer Healthcare
Published in: Cardiology and Therapy / Issue 1-2/2014
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-014-0028-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Changing Role for Endomyocardial Biopsy in the Diagnosis of Giant-Cell Myocarditis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2014

Prognosis of Troponin-Positive Patients with Non-Obstructive Coronary Artery Disease

Do We Currently Have Guidelines to Select an Adequate Prosthetic Valve to Surgically Treat Active Infective Endocarditis?

Percutaneous Coronary Intervention in Spontaneous Coronary Artery Dissection: Role of Intravascular Ultrasound

Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?

Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt

Aorta-to-Left Atrial Fistula Caused by Air Gun Pellet Cardiac Injury

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page